Paul Blanche

Paul Blanche

Auto-generated profile, based on publicly available information

Paul Blanche

Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2013 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
PBPaul Blanche
Paul Blanche
JDJean‐François Dartigues
Jean‐François Dartigues
HJHélène Jacqmin‐Gadda
Hélène Jacqmin‐Gadda

12 April 2018 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
FBFrancois-Clement Bidard
Francois-Clement Bidard
SMStefan Michiels
Stefan Michiels
SRSabine Riethdorf
Sabine Riethdorf
VMVolkmar Mueller
Volkmar Mueller
LELaura J Esserman
Laura J Esserman
KPKlaus Pantel
Klaus Pantel
We conducted a meta-analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemotherapy (NCT) to assess the clinical validity of circulating tumor cell (CTC) detection as a prognostic marker. We collected individual patient data from 21 studies in which CTC detection by CellSearch was performed in early breast cancer patients treated with NCT. The primary end point was overall survival, analyzed according to CTC detection, using Cox regression models stratified by study. Secondary end points included distant disease–free survival, locoregional relapse–free interval, and pathological complete response. All statistical tests were two-sided. Data from patients were collected before NCT (n = 1574) and before surgery (n = 1200). CTC detection revealed one or more CTCs in 25.2% of patients before NCT; this was associated with tumor size (P < .001). The number of CTCs detected had a detrimental and decremental impact on overall survival (P < .001), distant disease–free survival (P < .001), and locoregional relapse–free interval (P < .001), but not on pathological complete response. Patients with one, two, three to four, and five or more CTCs before NCT displayed hazard ratios of death of 1.09 (95% confidence interval [CI] = 0.65 to 1.69), 2.63 (95% CI = 1.42 to 4.54), 3.83 (95% CI = 2.08 to 6.66), and 6.25 (95% CI = 4.34 to 9.09), respectively. In 861 patients with full data available, adding CTC detection before NCT increased the prognostic ability of multivariable prognostic models for overall survival (P < .001), distant disease–free survival (P < .001), and locoregional relapse–free interval (P = .008). CTC count is an independent and quantitative prognostic factor in early breast cancer patients treated by NCT. It complements current prognostic models based on tumor characteristics and response to therapy.

13 October 2014 in Biometrics
Verified
Journal Article
Closed access
PDF file
PBPaul Blanche
Paul Blanche
CPCécile Proust-Lima
Cécile Proust-Lima
LLLucie Loubère
Lucie Loubère
CBClaudine Berr
Claudine Berr
JDJean-François Dartigues
Jean-François Dartigues
HJHélène Jacqmin-Gadda
Hélène Jacqmin-Gadda

16 February 2018 in Biostatistics
Verified
Journal Article
Closed access
PDF file
PBPaul Blanche
Paul Blanche
MKMichael Kattan
Michael Kattan
TGThomas A Gerds
Thomas A Gerds
We show that the widely used concordance index for time to event outcome is not proper when interest is in predicting a |$t$|-year risk of an event, for example 10-year mortality. In the situation with a fixed prediction horizon, the concordance index can be higher for a misspecified model than for a correctly specified model. Impropriety happens because the concordance index assesses the order of the event times and not the order of the event status at the prediction horizon. The time-dependent area under the receiver operating characteristic curve does not have this problem and is proper in this context.

21 June 2013 in Biometrical Journal
Verified
Journal Article
Closed access
PDF file
PBPaul Blanche
Paul Blanche
JDJean‐François Dartigues
Jean‐François Dartigues
HJHélène Jacqmin‐Gadda
Hélène Jacqmin‐Gadda

11 January 2021 in European Heart Journal
Verified
Journal Article
Closed access
AHAnders Holt
Anders Holt
PBPaul Blanche
Paul Blanche
BZBochra Zareini
Bochra Zareini
DRDeepthi Rajan
Deepthi Rajan
MEMohammed El-Sheikh
Mohammed El-Sheikh
MLMorten Lamberts
Morten Lamberts
Aims: We aimed to investigate the long-term cardio-protective effect associated with beta-blocker (BB) treatment in stable, optimally treated myocardial infarction (MI) patients without heart failure (HF). Methods and results: Using nationwide registries, we included patients with first-time MI undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) during admission and treated with both acetyl-salicylic acid and statins post-discharge between 2003 and 2018. Patients with prior history of MI, prior BB use, or any alternative indication or contraindication for BB treatment were excluded. Follow-up began 3 months following discharge in patients alive, free of cardiovascular (CV) events or procedures. Primary outcomes were CV death, recurrent MI, and a composite outcome of CV events. We used adjusted logistic regression and reported standardized absolute risks and differences (ARD) 3 years after MI. Overall, 30 177 stable, optimally treated MI patients were included (58% acute PCI, 26% sub-acute PCI, 16% CAG without intervention). At baseline, 82% of patients were on BB treatment (median age 61 years, 75% male) and 18% were not (median age 62 years, 68% male). BB treatment was associated with a similar risk of CV death, recurrent MI, and the composite outcome of CV events compared with no BB treatment [ARD (95% confidence intervals)] correspondingly; 0.1% (−0.3% to 0.5%), 0.2% (−0.7% to 1.2%), and 1.2% (−0.2% to 2.7%). Conclusions: In this nationwide cohort study of stable, optimally treated MI patients without HF, we found no long-term effect of BB treatment on CV prognosis following the patients from 3 months to 3 years after MI admission.